Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.

Dejnirattisai W. et al, (2021), Lancet

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.

Stuart ASV. et al, (2021), Lancet

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.

Munro APS. et al, (2021), Lancet

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Clemens SAC. et al, (2021), Nature Communications, 12

Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial.

Hodgson SH. et al, (2021), Clin Transl Sci

Transmission of community- and hospital-acquired SARS-CoV-2 in hospital settings in the UK: A cohort study.

Mo Y. et al, (2021), PLoS Med, 18

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

Liu X. et al, (2021), Lancet, 398, 856 - 869

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

EWER K. et al, (2021), The Lancet

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.

Shaw RH. et al, (2021), Lancet, 397, 2043 - 2046

SARS-CoV-2 within-host diversity and transmission

Lythgoe KA. et al, (2021), Science (New York, N.Y.), 372

SARS-CoV-2 within-host diversity and transmission.

Lythgoe KA. et al, (2021), Science, 372

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Voysey M. et al, (2021), Lancet, 397, 881 - 891

Assessing COVID-19 cohorting strategies in a UK district general hospital during the first wave of COVID-19.

Davies T. et al, (2021), Clin Med (Lond), 21, 40 - 41

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.

Volz E. et al, (2021), Cell, 184, 64 - 75.e11

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.

Lumley SF. et al, (2020), The New England journal of medicine

The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers

Lumley SF. et al, (2020), Clinical Infectious Diseases

Preoperative COVID-19 CT screening in renal transplant recipients.

Tsakok MT. et al, (2020), Clin Radiol, 75, 868 - 870

Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study.

Eyre DW. et al, (2020), Elife, 9

Chest CT screening for COVID-19 in elective and emergency surgical patients: experience from a UK tertiary centre.

Chetan MR. et al, (2020), Clin Radiol, 75, 599 - 605

Load More

Include forthcoming?